<h1 id="atrial-fibrillation-and-anticoagulation">Atrial Fibrillation and Anticoagulation</h1>
<ul>
<li>Anticoagulation goal with <span class="drug">warfarin</span>: INR 2-3</li>
<li>If age &lt; 60 years and zero risk factors: No anticoagulation b/c low risk for CVA </li>
</ul>
<p><strong>Deciding on whether to anticoagulate with aspirin or warfarin:</strong></p>
<h2 id="weak-risk-factors">Weak Risk Factors</h2>
<ul>
<li>Female gender    </li>
<li>Age 65-74         </li>
<li>CAD               </li>
<li>Thyrotoxicosis</li>
</ul>
<p><strong>Treatment</strong></p>
<ul>
<li><span class="drug">warfarin</span> or <span class="drug">warfarin</span></li>
</ul>
<h2 id="moderate-risk-factors">Moderate Risk Factors</h2>
<ul>
<li>Age &gt; 75            </li>
<li>HTN                     </li>
<li>Heart failure           </li>
<li>LVEF ≤ 35%              </li>
<li>DM  </li>
</ul>
<p><strong>Treatment</strong></p>
<ul>
<li>1 Risk factor: <span class="drug">aspirin</span> or <span class="drug">warfarin</span></li>
<li>&gt; 1 Risk factor: <span class="drug">warfarin</span></li>
</ul>
<h2 id="high-risk-factors">High Risk Factors</h2>
<ul>
<li>Prior CVA        </li>
<li>Prior TIA         </li>
<li>Embolism          </li>
<li>Mitral stenosis   </li>
<li>Mech heart valve</li>
</ul>
<p><strong>Treatment</strong></p>
<ul>
<li><span class="drug">warfarin</span></li>
</ul>
<p>(<a href="http://circ.ahajournals.org/content/114/7/e257.full">AHA/ACC/ESC 2006 guidelines</a>)</p>
<h2 id="background">Background</h2>
<p><strong>Atrial Fibrillation</strong> (AF) = <strong>5x</strong> risk for CVA and increases with age </p>
<ul>
<li>Patients with persistent and paroxysmal atrial fibrillation should be treated the same when it comes to deciding about anticoagulation. They have an equivalent risk of stroke.</li>
</ul>
<p><strong>Stroke risk factors for patients with AF: </strong></p>
<ul>
<li>Prior CVA or TIA</li>
<li>HTN</li>
<li>Age ≥75</li>
<li>CHF</li>
<li>Poor LV function</li>
<li>DM</li>
</ul>
<h2 id="chads2-stroke-risk-stratification-scheme">CHADS2 stroke risk stratification scheme</h2>
<ul>
<li><strong>C</strong> = Congestive heart failure (1 pt)</li>
<li><strong>H</strong> = Hypertension (1 pt)</li>
<li><strong>A </strong>= Age ≥ 75 (1 pt)</li>
<li><strong>D </strong>= DM (1 pt)</li>
<li><strong>S2</strong> = prior Stroke or TIA (2 pts)</li>
</ul>
<p><img src="https://d2p53dh3qxfm0x.cloudfront.net/uploads/img/1jx/5/m/41833411-397e-52ca-866b-0fe62dacc52e/640.png" alt="">
(<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11401607">Gage et al., JAMA, 2001</a>)</p>
<h2 id="references">References</h2>
<ul>
<li><a href="http://circ.ahajournals.org/content/114/7/e257.full">ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19111769">Waldo AL. Anticoagulation: Stroke Prevention in Patients with Atrial Fibrillation. Cardiol Clin 2009; 27:125-35.</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=11401607">Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70.</a></li>
</ul>
